NZ731591A - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone - Google Patents

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Info

Publication number
NZ731591A
NZ731591A NZ731591A NZ73159115A NZ731591A NZ 731591 A NZ731591 A NZ 731591A NZ 731591 A NZ731591 A NZ 731591A NZ 73159115 A NZ73159115 A NZ 73159115A NZ 731591 A NZ731591 A NZ 731591A
Authority
NZ
New Zealand
Prior art keywords
benzoic acid
oxycodone
conjugates
heteroaryl carboxylic
compound
Prior art date
Application number
NZ731591A
Other languages
English (en)
Inventor
Jaroslaw Kanski
Andrea K Martin
Sven Guenther
Bindu Bera
Sanjib Bera
Travis Mickle
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of NZ731591A publication Critical patent/NZ731591A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04Salts; Organic complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ731591A 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone NZ731591A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084246P 2014-11-25 2014-11-25
US201462084216P 2014-11-25 2014-11-25
PCT/US2015/062637 WO2016086113A1 (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Publications (1)

Publication Number Publication Date
NZ731591A true NZ731591A (en) 2018-06-29

Family

ID=56075034

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ731591A NZ731591A (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Country Status (18)

Country Link
US (3) US9850252B2 (enExample)
EP (1) EP3223819A4 (enExample)
JP (2) JP6400848B2 (enExample)
KR (2) KR101976101B1 (enExample)
CN (1) CN106999486A (enExample)
AU (1) AU2015353502B2 (enExample)
BR (1) BR112017011069A2 (enExample)
CA (1) CA2967424C (enExample)
CL (1) CL2017001353A1 (enExample)
CO (1) CO2017005201A2 (enExample)
IL (1) IL252470B (enExample)
MX (1) MX2017006520A (enExample)
NZ (1) NZ731591A (enExample)
PH (1) PH12017500963A1 (enExample)
RU (1) RU2683317C2 (enExample)
SG (1) SG11201704178UA (enExample)
WO (1) WO2016086113A1 (enExample)
ZA (1) ZA201703154B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
EP3223819A4 (en) 2014-11-25 2018-04-25 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
WO2018071879A1 (en) * 2016-10-14 2018-04-19 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
MX2020000638A (es) * 2017-07-20 2020-07-29 Suzhou Runxindatai Pharmaceutics Ltd Co Profármacos opioides de acción prolongada resistentes al abuso.
MX2020008706A (es) 2018-02-23 2020-09-25 Rhodes Tech Nuevos compuestos de opioides y sus usos.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (enExample)
US1731152A (en) 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US20040254182A1 (en) 2000-01-28 2004-12-16 Mulvihill Mark Joseph Enhanced propertied pharmaceuticals
EP1709957A3 (en) 2001-06-05 2007-02-14 Control Delivery Systems Sustained-release analgesic compounds
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
EP1531844B1 (en) 2002-02-22 2014-08-20 Shire LLC Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1782834A3 (en) 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
EP1675555A4 (en) 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
EP1677768A4 (en) 2003-10-03 2011-06-29 Elite Lab Inc PROLONGED RELEASE OPIOID FORMULATIONS AND METHOD OF USING THE FORMULATIONS
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
JP2009533443A (ja) * 2006-04-10 2009-09-17 シャイア エルエルシー 一置換及び二置換のオキシコドン化合物及び組成物
DK2046393T3 (da) 2006-05-26 2014-05-12 Signature Therapeutics Inc Kontrolleret frigivelse af phenol-opioider
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
EP2222678B1 (en) 2007-12-17 2016-03-09 Mallinckrodt LLC Processes for the production of (+)-'nal' morphinan compounds
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US20120142720A1 (en) * 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
US8623888B2 (en) 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
CN103384472B (zh) * 2011-01-11 2016-01-20 特色疗法股份有限公司 包含酶可裂解的羟考酮药物前体的组合物
CA2856608C (en) 2011-10-26 2017-05-16 Travis Mickle Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
EP3223819A4 (en) 2014-11-25 2018-04-25 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Also Published As

Publication number Publication date
US20190048018A1 (en) 2019-02-14
SG11201704178UA (en) 2017-06-29
ZA201703154B (en) 2019-03-27
RU2017122144A (ru) 2018-12-26
CA2967424C (en) 2023-05-02
US10144740B2 (en) 2018-12-04
PH12017500963A1 (en) 2017-10-18
AU2015353502B2 (en) 2018-09-27
JP6400848B2 (ja) 2018-10-03
US10544153B2 (en) 2020-01-28
RU2017122144A3 (enExample) 2018-12-26
BR112017011069A2 (pt) 2018-07-10
EP3223819A1 (en) 2017-10-04
KR101976101B1 (ko) 2019-05-09
CO2017005201A2 (es) 2017-08-31
KR20190049944A (ko) 2019-05-09
US20160168160A1 (en) 2016-06-16
CA2967424A1 (en) 2016-06-02
JP2017535593A (ja) 2017-11-30
IL252470A0 (en) 2017-07-31
RU2683317C2 (ru) 2019-03-28
US20180065975A1 (en) 2018-03-08
WO2016086113A1 (en) 2016-06-02
KR20170094249A (ko) 2017-08-17
CN106999486A (zh) 2017-08-01
AU2015353502A1 (en) 2017-05-25
EP3223819A4 (en) 2018-04-25
US9850252B2 (en) 2017-12-26
CL2017001353A1 (es) 2018-01-05
JP2018199719A (ja) 2018-12-20
IL252470B (en) 2019-08-29
MX2017006520A (es) 2017-08-09

Similar Documents

Publication Publication Date Title
NZ731591A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
HK1244708A1 (zh) 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
PH12018500061A1 (en) Oxysterols and methods of use thereof
HK1255500A1 (zh) 氧固醇及其使用方法
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
EP3412668A3 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
WO2013106761A3 (en) Antimicrobial agents
HK1220136A1 (zh) 治疗b2-缓激肽受体介导的血管性水肿的方法
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2014201016A3 (en) Inhibitors of the mitf molecular pathway
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
NZ707832A (en) 2-pyridone compound
MX360889B (es) Forma cristalina de un compuesto usado como un antagonista del receptor mineralocorticoide y metodo de preparacion de la misma.
WO2017085733A3 (en) Analgesic lipoic acid derivatives and the preparation thereof
WO2014060942A3 (en) Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
CR20200565A (es) Coposiciones antimicrobianas con agentes efervescentes (divisional exp. 2016-0592)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed